Induction of monocyte proliferation and HIV expression by IL-3 does not interfere with anti-viral activity of zidovudine

29Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Myelosuppression is a major symptom in the acquired immunodeficiency syndrome (AIDS). Moreover zidovudine, an anti-retroviral drug used to treat AIDS patients has myelosuppressive side effects. Therefore treatment with IL-3, a multi-lineage hemopoietic growth factor may be beneficial for zidovudine-treated individuals. In this study we examined the effect of IL-3 on human immunodeficiency virus (HIV) expression. The proliferative response to rIL-3 and the effects on the replication of the monocytotropic HIV variant. HTLV-III Ba-L, in the absence or presence of the anti-retroviral drug zidovudine was studied in purified human peripheral blood monocytes. Zidovudine concentrations sufficient for complete inhibition of HIV replication did not affect rIL-3 induced monocyte proliferation. Although rIL-3, like rGM-CSF, was able to augment HIV expression in monocytes. it did not interfere with the anti-retroviral activity of zidovudine. These data indicate that rIL-3 is a potential candidate for use in myelosupportive therapy in AIDS patients treated with anti-retroviral drugs. © 1990 by The American Society of Hematology.

Cite

CITATION STYLE

APA

Schuitemaker, H., Kootstra, N. A., Van Oers, M. H. J., Van Lambalgen, R., Tersmette, M., & Miedema, F. (1990). Induction of monocyte proliferation and HIV expression by IL-3 does not interfere with anti-viral activity of zidovudine. Blood, 76(8), 1490–1493. https://doi.org/10.1182/blood.v76.8.1490.bloodjournal7681490

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free